Closely monitor patients w/ a history of renal impairment for skeletal muscle effects. Discontinue if markedly elevated creatine phosphokinase levels occur or myopathy is diagnosed or suspected; patient developed interstitial lung disease. Increased risk of myopathy w/ concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, telaprevir, elbasvir, grazoprevir, combination of HIV protease inhibitors including saquinavir/ritonavir, lopinavir/ritonavir, tipranavir/ritonavir, darunavir/ritonavir, fosamprenavir & fosamprenavir/ritonavir, niacin or azole antifungals. Carefully monitor patients for signs or symptoms of muscle pain, tenderness or weakness particularly during initial mth of therapy & during any periods of upward dosage titration. Concomitant use w/ colchicine; drugs that may decrease levels of activity of endogenous steroid hormones eg, ketoconazole, spironolactone & cimetidine; fenofibrate, other fibrates; gemfibrozil; fusidic acid. Temporarily w/hold or discontinue use in patient w/ an acute, serious condition suggestive of myopathy or having a risk factor predisposing to development of renal failure secondary to rhabdomyolysis (eg, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders & uncontrolled seizures). Perform liver function tests prior to initiation of therapy & periodically thereafter. Promptly interrupt therapy if serious liver injury w/ clinical symptoms &/or hyperbilirubinemia or jaundice occurs during therapy. Substantial alcohol consumption &/or history of liver disease. Increase in HbA1c & fasting serum glucose levels. Consider potential risk of hemorrhagic stroke before initiating treatment in patients w/ recent (1-6 mth) stroke or transient ischemic attack. Can cause elevations in ALT/AST, alkaline phosphatase, GGT, bilirubin & creatine kinase. Monitor INR in concomitant use w/ warfarin, another coumarin anticoagulant or fluindione. Some adverse effects may affect ability to drive or operate machinery. Not recommended in patients w/ moderate or severe hepatic impairment. Ped patient.